CD19 epitope masking by tafasitamab leads to delays in subsequent use of CD19 CAR T-cell therapy in two patients with aggressive mature B-cell lymphomas

Click to increase image sizeClick to decrease image size

Author contributions

KF conceived and designed the study, drafted the manuscript, prepared figures, edited and revised the manuscript. LP conceived and designed the study, drafted the manuscript, edited and revised the manuscript. AQ analyzed data, prepared figures and approved the manuscript. SR conceived of the study and approved the manuscript. GvK edited and approved the manuscript. GS edited and approved the manuscript. AD analyzed data, edited and approved the manuscript. NEL performed laboratory studies, analyzed data and approved the manuscript.

Disclosure statement

Kelly N. Fitzgerald, Andres E. Quesada, Natasha E. Lewis and Sandeep Raj report no conflicts of interest.

Gottfried von Keudell reports personal fees from Merck, personal fees for Pharmacyclics, and personal fees from Morphosys outside the submitted work.

M. Lia Palomba reports personal fees from Novartis, personal fees and other from Merck & Co. Inc., personal fees and others from Pharmacyclics, personal fees and others from Kite, outside the submitted work; Dr. Palomba has intellectual property interests (by virtue of immediate family member interests) related to CARs (Chimeric Antigen Receptors) and TCRs (T cell Receptors) that Memorial Sloan Kettering Cancer Center (MSK) has licensed to Juno Therapeutics.

Ahmet Dogan reports personal fees from Corvus Pharmaceuticals, Physicians’ Education Resource, Seattle Genetics, Takeda, Roche, EUSAPharma, PeerView, and research support from Roche and Takeda.

Gilles Salles has received financial compensations for participating in advisory boards or consulting from Abbvie, Allogene, Autolus, Beigene, BMS/Celgene, Debiopharm, Genmab, Kite/Gilead, Incyte, Janssen, Milteniy, Morphosys, Novartis, Roche, Velosbio. He has received financial compensations for participation in educational events from Abbvie, Celgene, Gilead, Janssen, Kite, Morphosys, Novartis, Roche

Additional information

Funding

We would like to thank the Janice Stanton Fund for supporting this work. This work was supported in part through the NIH/NCI Cancer Center Support Grant [P30 CA008748] and MSK Lymphoma SPORE [P50 CA192937] (A.D.) and Farmer Family Foundation (A.D.).